Lyndsay N. Harris

Research interests

Publications

• Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.00762

• Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.03010

• Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2) –Positive Breast Cancer

  JAMA Network Open · 2019 · 10.1001/jamanetworkopen.2019.2561

• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.65.2289

• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

  Cancer Cell · 2016 · https://doi.org/10.1016/j.ccell.2016.02.006

• Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.62.1268

• Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.61.1459

• HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.26.2154

• Trastuzumab-Induced HER Reprogramming in “Resistant” Breast Carcinoma Cells

  Cancer Research · 2009 · 10.1158/0008-5472.can-08-1056

• Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin

  Cell · 2008 · 10.1016/j.cell.2008.04.045

• Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.6699

• Molecular Definition of Breast Tumor Heterogeneity

  Cancer Cell · 2007 · https://doi.org/10.1016/j.ccr.2007.01.013

• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.14.2364

• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-1304

• Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.06.5664

• Requirement for CDK4 kinase function in breast cancer

  Cancer Cell · 2006 · 10.1016/j.ccr.2005.12.012

• Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data

  BMC Bioinformatics · 2006 · 10.1186/1471-2105-7-197

• A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers

  Nature Genetics · 2006 · https://doi.org/10.1038/ng1861

• Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.08.048

• Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.02.018

• Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

  Cancer · 2003 · 10.1002/cncr.11436

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.20.3.719

• Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2003.03.124

• Social support as a buffer to the psychological impact of stressful life events in women with breast cancer

  Cancer · 2001 · 10.1002/1097-0142(20010115)91:2<443::aid-cncr1020>3.0.co;2-z

• Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

  Cancer · 2001 · 10.1002/cncr.10201

Current projects

No projects listed.